288 related articles for article (PubMed ID: 24359082)
21. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
Singh SK; Luisi DL; Pak RH
Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
[TBL] [Abstract][Full Text] [Related]
22. Antibody conjugates with unnatural amino acids.
Hallam TJ; Wold E; Wahl A; Smider VV
Mol Pharm; 2015 Jun; 12(6):1848-62. PubMed ID: 25898256
[TBL] [Abstract][Full Text] [Related]
23. Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody.
Thompson P; Bezabeh B; Fleming R; Pruitt M; Mao S; Strout P; Chen C; Cho S; Zhong H; Wu H; Gao C; Dimasi N
Bioconjug Chem; 2015 Oct; 26(10):2085-96. PubMed ID: 26340339
[TBL] [Abstract][Full Text] [Related]
24. Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.
Puthenveetil S; Musto S; Loganzo F; Tumey LN; O'Donnell CJ; Graziani E
Bioconjug Chem; 2016 Apr; 27(4):1030-9. PubMed ID: 26942771
[TBL] [Abstract][Full Text] [Related]
25. Investigation of High Molecular Weight Size Variant Formation in Antibody-Drug Conjugates: Microbial Transglutaminase-Mediated Crosslinking.
Zhao Y; Kim S; Zheng X; Kim SH; Han A; Chen TH; Wang S; Zhong J; Qiu H; Li N
J Pharm Sci; 2023 Oct; 112(10):2629-2636. PubMed ID: 37586591
[TBL] [Abstract][Full Text] [Related]
26. Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates.
Chen T; Su D; Gruenhagen J; Gu C; Li Y; Yehl P; Chetwyn NP; Medley CD
J Pharm Biomed Anal; 2016 Jan; 117():304-10. PubMed ID: 26406314
[TBL] [Abstract][Full Text] [Related]
27. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering.
Benjamin SR; Jackson CP; Fang S; Carlson DP; Guo Z; Tumey LN
Mol Pharm; 2019 Jun; 16(6):2795-2807. PubMed ID: 31067063
[TBL] [Abstract][Full Text] [Related]
28. In vivo testing of drug-linker stability.
Abecassis PY; Amara C
Methods Mol Biol; 2013; 1045():101-16. PubMed ID: 23913143
[TBL] [Abstract][Full Text] [Related]
29. [Advances in the study of site-specific antibody-drug conjugates].
Sun Y; Huang R; Sun BW
Yao Xue Xue Bao; 2015 Oct; 50(10):1225-31. PubMed ID: 26837166
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.
Xu K; Liu L; Dere R; Mai E; Erickson R; Hendricks A; Lin K; Junutula JR; Kaur S
Bioanalysis; 2013 May; 5(9):1057-71. PubMed ID: 23641696
[TBL] [Abstract][Full Text] [Related]
31. State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.
Deslignière E; Ehkirch A; Duivelshof BL; Toftevall H; Sjögren J; Guillarme D; D'Atri V; Beck A; Hernandez-Alba O; Cianférani S
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073805
[TBL] [Abstract][Full Text] [Related]
32. Analytical and bioanalytical technologies for characterizing antibody-drug conjugates.
Alley SC; Anderson KE
Curr Opin Chem Biol; 2013 Jun; 17(3):406-11. PubMed ID: 23570980
[TBL] [Abstract][Full Text] [Related]
33. Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates?
D'Atri V; Pell R; Clarke A; Guillarme D; Fekete S
J Chromatogr A; 2019 Feb; 1586():149-153. PubMed ID: 30554777
[TBL] [Abstract][Full Text] [Related]
34. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
McCombs JR; Owen SC
AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
[TBL] [Abstract][Full Text] [Related]
35. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.
Fujii T; Matsuda Y; Seki T; Shikida N; Iwai Y; Ooba Y; Takahashi K; Isokawa M; Kawaguchi S; Hatada N; Watanabe T; Takasugi R; Nakayama A; Shimbo K; Mendelsohn BA; Okuzumi T; Yamada K
Bioconjug Chem; 2023 Mar; 34(4):728-38. PubMed ID: 36894324
[TBL] [Abstract][Full Text] [Related]
36. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.
Gorovits B; Alley SC; Bilic S; Booth B; Kaur S; Oldfield P; Purushothama S; Rao C; Shord S; Siguenza P
Bioanalysis; 2013 May; 5(9):997-1006. PubMed ID: 23641692
[TBL] [Abstract][Full Text] [Related]
37. Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs.
Mills BJ; Kruger T; Bruncko M; Zhang X; Jameel F
J Pharm Sci; 2020 May; 109(5):1662-1672. PubMed ID: 32027921
[TBL] [Abstract][Full Text] [Related]
38. Current ADC Linker Chemistry.
Jain N; Smith SW; Ghone S; Tomczuk B
Pharm Res; 2015 Nov; 32(11):3526-40. PubMed ID: 25759187
[TBL] [Abstract][Full Text] [Related]
39. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.
Stephan JP; Kozak KR; Wong WL
Bioanalysis; 2011 Mar; 3(6):677-700. PubMed ID: 21417735
[TBL] [Abstract][Full Text] [Related]
40. Current Status: Site-Specific Antibody Drug Conjugates.
Schumacher D; Hackenberger CP; Leonhardt H; Helma J
J Clin Immunol; 2016 May; 36 Suppl 1():100-7. PubMed ID: 27003914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
